Drug safety evaluation of ziprasidone

Bibliography

• Davis R, Markham A. Ziprasidone. CNS Drugs 1997;8(2):153-9
   PubMed Web of Science ®Google Scholar
• Remington G. ‘Atypical’ antipsychotics: where does ziprasidone fit? Expert Rev Neurother 2002;10(1):13-24
   Google Scholar
• Greenberg WM, Citrome L. Ziprasidone for schizophrenia and bipolar disorder – a review of the clinical trials. CNS Drug Rev 2007;13(2):137-77
   PubMedGoogle Scholar
• Citrome L. Ziprasidone HCl capsules for the adjunctive maintenance treatment of bipolar disorder in adults. Expert Rev Neurother 2010;10(7):1031-7
   PubMed Web of Science ®Google Scholar
• Citrome L. Using ziprasidone effectively: the food effect and dose response. Adv Ther 2009;26(8):739-48
   PubMed Web of Science ®Google Scholar
• Pfizer. Geodon: US Package Insert for Geodon (ziprasidone HCl) and Geodon (ziprasidone mesylate) for injection. LAB-0273-17.0; revised December 2010. Available from: http://www.pfizer.com/files/products/uspi_geodon.pdf. [Last accessed 21 December 2010]
   Google Scholar
• Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge University Press, Cambridge; 2008
   Google Scholar
• Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004;9(Suppl 11):6-14
   PubMed Web of Science ®Google Scholar
• Citrome L, Yang R, Glue P, Effect of ziprasidone dose on all-cause discontinuation rates in acute schizophrenia and schizoaffective disorder: a post-hoc analysis of 4 fixed-dose randomized clinical trials. Schizophr Res 2009;111(1-3):39-45
   PubMed Web of Science ®Google Scholar
• Lesem MD, Zajecka JM, Swift RH, Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001;62(1):12-18
   PubMed Web of Science ®Google Scholar
• Daniel DG, Potkin SG, Reeves KR, Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology 2001;155(2):128-34
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Versiani M, Potkin S, For the Ziprasidone in Mania study group. Ziprasidone in the treatment of acute bipolar mania: a three–week, placebo–controlled, double–blind, randomized trial. Am J Psychiatry 2003;160(4):741-8
   PubMed Web of Science ®Google Scholar
• Potkin S, Keck P, Segal S, Ziprasidone in Acute Bipolar Mania: A 21-day randomized, double-blind, placebo-controlled replication trial. J Clin Psychopharmacol 2005;25(4):301-10
   PubMed Web of Science ®Google Scholar
• Bowden CL, Vieta E, Ice KS, Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010;71(2):130-7
   PubMed Web of Science ®Google Scholar
• Pfizer Healthcare Ireland. Geodon Capsules 20mg, 40mg, 60mg, 80mg Summary of Product Characteristics; revised 06 November 2009. Available from: http://www.medicines.ie/medicine/6166/SPC/GEODON+Capsules+20mg,+40mg,+60mg,+80mg/. [Last accessed 22 December 2010]
   Google Scholar
• Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
   PubMed Web of Science ®Google Scholar
• Andersohn F, Schmedt N, Weinmann S, Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol 2010;30(1):68-71
   PubMed Web of Science ®Google Scholar
• Kaufman KR, Stern L, Mohebati A, Ziprasidone-induced priapism requiring surgical treatment. Eur Psychiatry 2006;21(1):48-50
   PubMed Web of Science ®Google Scholar
• Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4(3):229-37
   PubMedGoogle Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158(11):1774-82
   PubMed Web of Science ®Google Scholar
• Pfizer. FDA Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox® capsules (Ziprasidone HCl). New York: Pfizer, Inc., July 19, 2000. Available from: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf. [Last accessed 22 December 2010]
   Google Scholar
• Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics 2006;47(3):264-8
   PubMed Web of Science ®Google Scholar
• Alipour A, Cruz R, Lott RS. Torsade de pointes after ziprasidone overdose with coingestants. J Clin Psychopharmacol 2010;30(1):76-7
   PubMed Web of Science ®Google Scholar
• Manini AF, Raspberry D, Hoffman RS, QT prolongation and Torsades de Pointes following overdose of ziprasidone and amantadine. J Med Toxicol 2007;3(4):178-81
   PubMedGoogle Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy 2010;30(2):127-35
   PubMed Web of Science ®Google Scholar
• Levy WO, Robichaux-Keene NR, Nunez C. No significant QTc interval changes with high-dose ziprasidone: a case series. J Psychiatr Pract 2004;10(4):227-32
   PubMedGoogle Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, Effects of high dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Therapeutics 2010;32(3):472-91
   PubMed Web of Science ®Google Scholar
• Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003;17(6):423-30
   PubMed Web of Science ®Google Scholar
• Arato M, O’Connor R, Meltzer HY. ZEUS study group. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002;17(5):207-15
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
   PubMed Web of Science ®Google Scholar
• Addington DE, Pantelis C, Dineen M, Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry 2004;65(12):1624-33
   PubMed Web of Science ®Google Scholar
• Hirsch SR, Kissling W, Bauml J, A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry 2002;63(6):516-23
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Lipkovich I, Edwards SB, A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-62
   PubMed Web of Science ®Google Scholar
• Simpson GM, Weiden P, Pigott T, Six–month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162(8):1535-8
   PubMed Web of Science ®Google Scholar
• Breier A, Berg PH, Thakore JH, Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-22
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
   PubMed Web of Science ®Google Scholar
• Sanchez-Barranco P. New onset of diabetes mellitus with ziprasidone: a case report. J Clin Psychiatry 2005;66(2):268-9
   PubMed Web of Science ®Google Scholar
• American diabetes association, American psychiatric association, American association of clinical endocrinologists, North American association for the study of obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27(2):596-601
   PubMed Web of Science ®Google Scholar
• Strom BL, Eng SM, Faich G, Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry 2010. [Epub ahead of print]
   Google Scholar
• Citrome L, Jaffe A, Levine J. How dosing of ziprasidone in a state hospital system differs from product labeling. J Clin Psychiatry 2009;70(7):975-82
   PubMed Web of Science ®Google Scholar
• Deutschman DA, Deutschman DH. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders. J Clin Psychopharmacol 2007;27(5):513-14
   PubMed Web of Science ®Google Scholar
• Mech AW. High-dose ziprasidone monotherapy in bipolar I disorder patients with depressed or mixed episodes. J Clin Psychopharmacol 2008;28(2):240-1
   PubMed Web of Science ®Google Scholar
• Rosenfield PJ, Girgis RR, Gil R. High-dose ziprasidone-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(2):546-7
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006;2(4):427-43
   PubMedGoogle Scholar
• Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract 2009;63(8):1237-48
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009;63(12):1762-84
   PubMed Web of Science ®Google Scholar
• Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210
   PubMed Web of Science ®Google Scholar
• Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006;17(3):337-40
   PubMed Web of Science ®Google Scholar
• Goff D. High-dose ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms (HDZ). NCT00403546. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00403546. [Last accessed 25 January 2011]
   Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10(12):1917-28
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
   PubMed Web of Science ®Google Scholar